Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
4
Issued Date
2023-01-01
Resource Type
ISSN
09395555
eISSN
14320584
Scopus ID
2-s2.0-85159668075
Pubmed ID
37202499
Journal Title
Annals of Hematology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of Hematology (2023)
Suggested Citation
Rattanathammethee T., Norasetthada L., Bunworasate U., Wudhikarn K., Julamanee J., Noiperm P., Lanamtieng T., Phiphitaporn P., Navinpipat M., Kanya P., Jit-ueakul D., Wongkhantee S., Suwannathen T., Chaloemwong J., Wong P., Makruasi N., Khuhapinant A., Prayongratana K., Niparuck P., Kanitsap N., Suwanban T., Intragumtornchai T. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG). Annals of Hematology (2023). doi:10.1007/s00277-023-05273-8 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82892
Title
Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
Author(s)
Rattanathammethee T.
Norasetthada L.
Bunworasate U.
Wudhikarn K.
Julamanee J.
Noiperm P.
Lanamtieng T.
Phiphitaporn P.
Navinpipat M.
Kanya P.
Jit-ueakul D.
Wongkhantee S.
Suwannathen T.
Chaloemwong J.
Wong P.
Makruasi N.
Khuhapinant A.
Prayongratana K.
Niparuck P.
Kanitsap N.
Suwanban T.
Intragumtornchai T.
Norasetthada L.
Bunworasate U.
Wudhikarn K.
Julamanee J.
Noiperm P.
Lanamtieng T.
Phiphitaporn P.
Navinpipat M.
Kanya P.
Jit-ueakul D.
Wongkhantee S.
Suwannathen T.
Chaloemwong J.
Wong P.
Makruasi N.
Khuhapinant A.
Prayongratana K.
Niparuck P.
Kanitsap N.
Suwanban T.
Intragumtornchai T.
Author's Affiliation
Ramathibodi Hospital
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Nakornping Hospital
Faculty of Medicine, Khon Kaen University
Naresuan University
Chulabhorn Royal Academy
Vajira Hospital
Khon Kaen Regional Hospital
Thammasat University
Phramongkutklao College of Medicine
Prince of Songkla University
Faculty of Medicine, Srinakharinwirot University
Rajavithi Hospital
Faculty of Medicine, Chulalongkorn University
Chiangrai Prachanukroh Hospital
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Nakornping Hospital
Faculty of Medicine, Khon Kaen University
Naresuan University
Chulabhorn Royal Academy
Vajira Hospital
Khon Kaen Regional Hospital
Thammasat University
Phramongkutklao College of Medicine
Prince of Songkla University
Faculty of Medicine, Srinakharinwirot University
Rajavithi Hospital
Faculty of Medicine, Chulalongkorn University
Chiangrai Prachanukroh Hospital
Other Contributor(s)
Abstract
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. Thirty-five patients who received Pola-based treatment were included in the study, and their data were compared to 180 matched patients who received non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. The study found a significantly higher ORR in Pola-based salvage treatments compared to non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also significantly superior in the Pola group, with longer median PFS and OS than the control group. Grades 3–4 adverse events (AEs) were mainly hematological, and they were tolerable. In conclusion, this study provides real-world evidence of the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. The results of this study are promising and suggest that Pola-based salvage treatment could be a viable option for R/R DLBCL patients who have limited treatment options.